Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atigotatug + nivolumab fixed-dose combination with carboplatin and etoposide versus atezolizumab with carboplatin and etoposide in first-line extensive-stage small cell lung cancer
2024-515740-23-00Phase 3Authorised
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 26
01
Overview
Phase 3, randomised, double-blind trial of bms-986012 + nivolumab, atezolizumab, carboplatin and etoposide in small cell lung cancer (SCLC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Overall survival. Planned start Mar 2025; status: authorised.
02
Drugs
bms-986012 + nivolumabatezolizumabcarboplatinetoposide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2024-515740-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515740-23-00.